Allergic Rhinitis – Comprehensive Study Notes

Introduction and Unified Allergic Airway

Allergic rhinitis (AR) is an IgE-mediated inflammatory condition of the nasal mucosa triggered by inhaled allergens already encountered by the patient. Reported global prevalence spans $0.8\%–39.7\%$, with Western Europe averaging $23\%$. The disease rarely exists in isolation; ocular involvement (allergic conjunctivitis) and lower-airway involvement (allergic asthma) frequently co-occur, leading to the concept of a unified allergic airway. Shared epidemiology, pathophysiology and, often, a shared treatment strategy justify considering these entities as a spectrum rather than discrete disorders.

Definitions and Classification

Rhinitis is defined clinically when ≥2 of anterior/posterior rhinorrhoea, sneezing, nasal blockage and/or nasal itching are present for ≥2 consecutive days, for >1 h on most days. When provoked by allergen-driven IgE reactivity the condition is termed allergic rhinitis.

Classification (ARIA):

• Temporal pattern – Intermittent (IAR) vs Persistent (PER)
  • IAR: symptoms <$4$ days week⁻¹ or <$4$ consecutive weeks year⁻¹
  • PER: symptoms >$4$ days week⁻¹ and >$4$ consecutive weeks year⁻¹
• Severity – Mild vs Moderate/Severe judged by impact on sleep, daily activities/leisure/sport, school/work performance and subjective ‘troublesome’ rating.

Population study figures: Mild-intermittent $10\%$, Mild-persistent $14\%$, Moderate/Severe-intermittent $17\%$, Moderate/Severe-persistent $59\%$. Approximately $75\%$ of sufferers therefore meet criteria for a persistent pattern.

Epidemiology and Prevalence

ISAAC Phases 1 & 3 documented marked international variation ($0.8\%–39.7\%$ in $13$–$14$ year-olds). Low-asthma countries such as Indonesia, Romania and Greece exhibit <$5\%$ asthma prevalence and similarly low AR rates; conversely the UK, Australia and New Zealand report asthma >$30\%$ and AR $15–20\%$. The steep 40-year rise in prevalence may now be plateauing.

Hypotheses explaining the rise:

• Hygiene hypothesis – reduced early microbial exposure skews immune maturation away from Th$1$ towards Th$2$ dominance ⇒ increased IgE sensitisation.
• Farm effect – early contact with livestock/soil microbes confers protection; consistent with larger family size, frequent infections and ‘unhygienic’ contact being protective.
• Helminths – chronic parasitic infection elevates ‘blocking’ IgG$4$ and down-regulates IgE responses; de-worming increases aeroallergen reactivity.

Pathophysiology

1. Sensitisation: allergen exposure in a genetically predisposed host → allergen-specific IgE production.
2. Primed mast cells: IgE binds high-affinity FcεRI receptors on mucosal mast cells.
3. Re-exposure → cross-linking → mast-cell degranulation with release of:
   • Pre-formed mediators: histamine, serine proteases, heparin
   • Newly-synthesised mediators: leukotriene $C<em>4$, prostaglandin $D</em>2$, thromboxane, platelet-activating factor (PAF).

Symptom correlates:

• Histamine – rapid sneezing, itching
• Leukotrienes/prostaglandins – sustained congestion/obstruction
• Mucosal leak – rhinorrhoea

Natural History and Genetics

Having one atopic parent increases a child’s risk three- to six-fold. Sensitisation requires environmental exposure; pollen-induced AR is rare <$2$ years because ≥$2$ pollen seasons are needed for priming.

‘Atopic march’: atopic eczema (infancy) → AR (childhood) → asthma (later childhood/adolescence). Adults with AR carry a three-fold risk of subsequent asthma. Some patients remit: $23.1\%$ lost AR symptoms over an $8$-year longitudinal study. Reactivity and severity generally wane with age.

Clinical Presentation

Core nasal symptoms: bilateral watery rhinorrhoea, paroxysmal sneezing, itching, obstruction. Children may simply report ‘a blocked nose’. Associated complaints: itchy eyes, pharyngeal itch, eustachian tube dysfunction, decreased smell, chronic cough, fatigue, snoring, halitosis, eczema.

Red-flag features (suggest alternative pathology): unilateral, mucopurulent or blood-streaked discharge, significant facial pain, frank epistaxis, anosmia.

History pearls:

• Seasonality identifies aero-pollen triggers.
• Morning obstruction suggests house-dust-mite laden bedding.
• Birch-pollen sufferers often report oral-allergy-syndrome to uncooked pome fruits, celery, nuts, carrot, etc.
• Drug-, hormonal-, occupational-, irritant- and infectious rhinitis mimic AR but lack IgE linkage.

Examination Findings

General inspection for eczema, allergic shiners, Dennie–Morgan folds or nasal ‘allergic salute’ crease. Anterior rhinoscopy/endoscopy:

• Mucosa often oedematous, pale/blue, thin watery secretions.
• Marked, fixed swelling may indicate turbinate hypertrophy or adenoidal tissue (in children).
• Endoscopy excludes polyps, tumours or suppurative sinus disease.
  If history of cough/wheeze, examine chest; consider spirometry.

Diagnostic Modalities

1. Skin-Prick Testing (SPT)

   • Positive wheal ≥$2$ mm bigger than saline control.
   • Test panel (UK): grass pollen, house dust mite, cat, dog; add cockroach, moulds, horse, etc. as clinically indicated.
   • Antihistamines must be withheld $7–10$ days pre-test.
   • Positive SPT = atopy; clinical relevance requires correlation.
   • $\approx25\%$ of adults have positive SPT; only $10–15\%$ symptomatic.

2. Serum specific IgE (RAST or fluorescent enzyme-immunoassay)

   • Positive ≥$0.35$ kU L$^{-1}$; useful when SPT contraindicated (dermographism, extensive eczema, antihistamine dependence).

3. Nasal Allergen Challenge

   • Gold standard yet rarely necessary; useful when strong clinical suspicion but negative SPT/RAST.
   • Objective measures: sneeze count, peak nasal inspiratory flow, rhinomanometry.

4. Ancillary tests (research/tertiary): mediator assays, nasal cytology, exhaled nitric oxide, etc.

Treatment Overview

ARIA 2008 algorithm advises step-wise management based on intermittent vs persistent pattern and severity. Core approaches:

1. Allergen avoidance/prevention
2. Pharmacotherapy
3. Immunotherapy
4. Surgery (selected obstruction cases)
5. Complementary/adjunctive measures

Allergen Avoidance Strategies

Indoor major allergens: house dust mite (HDM), cat/dog dander, cockroach, mould. Outdoor: pollens (tree—spring, grass—weeks of summer, weed/ragweed—late summer/autumn) and mould spores.

House-Dust-Mite Measures

• Weekly hot-wash bedding $55–60^{\circ}\text{C} (cold wash removes $90\%$ allergen; hot wash also exterminates mites).
• HDM-impermeable mattress/pillow covers (pore size ≤$6\,\mu\text{m}$).
• Humidity control: maintain indoor relative humidity <$50\%$.
• HEPA-filter vacuuming, damp-dusting, hard flooring, sun-exposure of carpets (>$3$ h) reduce mite load.

Pollen Control

• Keep windows shut at peak counts.
• Sunglasses reduce ocular deposition.
• Masks or air-conditioning useful in extreme seasons.

Pet, Cockroach & Mould Protocols

• Optimal: remove pet; if not, strict bedroom exclusion, frequent vacuuming, change clothes after animal contact.
• Cockroach: bait extermination, seal cracks, no food waste storage, wet-scrub allergens.
• Mould: dehumidify, repair leaks, $5\%$ ammonia wash, substitute carpets/wallpaper with hard surfaces/paint.

Evidence summary: despite measurable allergen reductions (e.g.
HDM cover study reduced mite antigen to $\approx30\%$ baseline), robust clinical benefit is unproven.

Pharmacological Treatments

Immunotherapy

• Subcutaneous (SCIT) and Sublingual (SLIT) equally efficacious; tailored to proven clinically relevant allergen (grass, HDM, cat, dog, tree pollen, etc.).
• Indications: moderate/severe disease poorly controlled or medication side-effects unacceptable.
• Protocol: updosing $2–4$ months → maintenance every $4–6$ weeks (SCIT) or daily (SLIT) × $3$ years; benefits persist post-therapy and may prevent new sensitisation and asthma evolution (risk reduction documented in children).
• Efficacy example: grass-pollen SCIT ↓ symptom score $32\%$, ↓ medication score $41\%$ vs placebo during peak season.
• Adverse events: local pruritus/erythema common; systemic reactions rare but mandate $\geq30$ min supervised observation and availability of adrenaline.

Anti-IgE (Omalizumab)

Monoclonal antibody neutralising free IgE. Monthly injections improve nasal and asthmatic symptoms but carry anaphylaxis risk and high cost; currently reserved for severe allergic asthma ± rhinitis.

Surgical Management

Surgery addresses fixed obstruction rather than allergy itself:

• Inferior turbinate reduction (submucosal cautery, radiofrequency, microdebrider) when fibrosis/irreversible hypertrophy persists.
• Polypoid mucosa occasionally excised. Decision guided by failure of medical decongestion during clinic evaluation.

Complementary and Adjunct Therapies

Randomised trials of homeopathy, acupuncture and herbal remedies have not demonstrated objective benefit, yet patient uptake remains high. Provide balanced counselling.

Special Populations

Pediatric Considerations

AR is the commonest paediatric allergic disease; comorbidity with asthma exacerbates disease burden. Differentiate from recurrent viral rhinitis and adenoidal hypertrophy (normal mucosa but obstruction). Skin-prick feasible on back; oral second-generation antihistamines first-line. Intranasal steroids with lowest systemic bioavailability—fluticasone (≥$4$ y), mometasone/triamcinolone (≥$6$ y)—preferred; avoid beclometasone due to documented growth delay. Monitor growth in any child on multiple steroid routes. SCIT usually deferred <$5$ y; SLIT under evaluation.

Pregnancy

Oestrogen-mediated ‘rhinitis of pregnancy’ may aggravate existing AR or present de novo; condition resolves post-partum. Opt for saline irrigation or short-course topical decongestant; if necessary, use low-bioavailability intranasal corticosteroid (budesonide carries most pregnancy safety data). Systemic antihistamines generally avoided although loratadine and cetirizine have reassuring safety profiles.

Best Clinical Practice Highlights

• Universal breastfeeding ≥$3$ months advocated; maternal antigen-avoidance diet shows no preventive benefit.
• Smoking cessation during pregnancy and infancy strongly advised although direct AR causality remains unproven.
• Allergen-avoidance regimes often fail to translate to clinical gain; consider as individualised trial rather than universal prescription.
• Food allergy rarely causes isolated rhinitis; investigate only when multisystem reactions present.
• Antihistamines most effective when taken continuously through exposure period; advise pre-season initiation in seasonal AR.
• Intranasal corticosteroids remain the single most effective monotherapy for nasal & ocular AR symptoms.
• Immunotherapy offers disease-modifying potential and should be contemplated in moderate/severe, poorly controlled cases.

Future Research Directions

• Efficacy of early-life allergen avoidance and occupational interventions in preventing allergic sensitisation.
• Optimal long-term use and combination strategy for antihistamines, corticosteroids, LTRAs and decongestants.
• Expanded indications, protocols and cost-effectiveness analyses for SCIT, SLIT and biologics (e.g. anti-IgE).
• Role of helminth-derived immunomodulators in therapy or prevention.
• Objective evaluation of complementary modalities.

Key Takeaways

• AR is a prevalent, systemic, IgE-mediated disorder with significant quality-of-life and socio-economic impact.
• History, exposure pattern and demonstration of sensitisation (SPT/IgE) establish the diagnosis; nasal examination mainly excludes alternatives.
• Front-line therapy combines trigger avoidance, scheduled oral/topical antihistamines and intranasal corticosteroids; add-on pharmacologic agents chosen symptom-specifically.
• Immunotherapy uniquely alters disease course and reduces future asthma/allergy burden.
• Management must consider comorbid asthma, paediatric growth, pregnancy safety and, occasionally, surgical airway optimisation.